A major study published in 2026 has concluded that the Meningitis B vaccine — commonly known as MenB — does not protect men from gonorrhoea infection, according to BBC News.
Background to the Assumption
The MenB vaccine had previously been offered to men considered at elevated risk of gonorrhoea, based on the hypothesis that it might confer some degree of cross-protection against the bacterium responsible for the sexually transmitted infection. That assumption appears to have rested on biological similarities between the pathogens involved, though the new research directly challenges whether any meaningful protection translates in practice.
What the Study Found
Scientists behind the research report that the vaccine does not prevent gonorrhoea infections among men. The findings raise significant questions about the rationale for deploying MenB vaccination as a preventive strategy against gonorrhoea in at-risk male populations.
The study is described as major in scope, suggesting its conclusions carry considerable weight within the field, though the research adds to an ongoing scientific conversation rather than settling all outstanding questions about vaccine cross-reactivity.
Implications for Public Health Strategy
If the findings hold up to further scrutiny, public health programmes that have incorporated MenB vaccination partly on the basis of potential gonorrhoea protection may need to be reassessed. Gonorrhoea rates have been a persistent concern in several countries, and the prospect of a vaccine offering incidental protection had been viewed as a potential additional tool in controlling transmission.
The study does not appear to question the established effectiveness of the MenB vaccine against meningococcal disease itself, for which it was originally developed and licensed. Its conclusions are specific to the question of gonorrhoea prevention in men.
Wider Context
Gonorrhoea, caused by the bacterium Neisseria gonorrhoeae, remains one of the most commonly reported sexually transmitted infections globally, and growing antimicrobial resistance has made treatment increasingly complex in some cases. The search for preventive measures, including vaccine-based approaches, has therefore attracted sustained research interest.
The 2026 study represents a notable setback for one avenue of that research, though scientists continue to investigate other potential vaccine candidates specifically designed to target gonorrhoea directly.